AbbVie’s (ABBV) stock has been under pressure for over a year on concerns about Humira’s patent expiration in Europe last year and the loss of protection from competition in the United States beginning in 2023. As a result of these concerns, AbbVie’s stock declined 38% from $123 down to the current price of $76.87. The sharp decline has the stock trading at a bargain valuation.
AbbVie is one of the leading pharma companies in the world. It’s growth however is in question as Humira slowly get biosimilar competition.